Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers

Area of Science:

• Molecular Biology
• Cancer Research
• Cellular Metabolism

Background:

• Activating mutations in the RAS oncogene are prevalent in various cancers and pose significant therapeutic challenges.
• RAS activation stimulates autophagy, a cellular degradation process crucial for cell survival under stress.
• Identifying regulators of RAS-induced autophagy is critical for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the role of casein kinase 1α (CK1α) as a regulator of oncogenic RAS-induced autophagy.
• To elucidate the molecular mechanisms by which CK1α influences RAS-driven autophagy.
• To evaluate the therapeutic potential of targeting CK1α in RAS-driven cancers.

Main Methods:

• Depletion and pharmacologic inhibition of CK1α in human cancer cell lines and fibroblasts.
• Analysis of autophagic flux and expression of autophagy-related genes.
• Investigation of the interaction between CK1α, FOXO3A, and the PI3K/AKT/mTOR pathway.
• Evaluation of therapeutic efficacy in murine xenograft models.

Main Results:

• CK1α acts as a negative regulator of oncogenic RAS-induced autophagy.
• CK1α inhibition enhances autophagic flux and increases the expression of FOXO3A-responsive genes.
• Oncogenic RAS signaling increases CK1α protein levels, which in turn phosphorylates and inhibits FOXO3A.
• Pharmacologic CK1α inactivation synergizes with lysosomotropic agents to inhibit tumor growth and induce cell death in preclinical models.

Conclusions:

• CK1α is a key component of a feedback loop regulating RAS-dependent autophagy.
• Targeting CK1α-mediated regulation of autophagy presents a promising therapeutic strategy for RAS-driven cancers.
• The combination of CK1α inhibitors and lysosomotropic agents warrants further clinical investigation for cancer treatment.